Scalable synthesis and structural characterization of reversible KLK6 inhibitors

Andreas Baumann1, Daniel Isak1, Jasmin Lohbeck1

  • 1Cancer Drug Development Group, German Cancer Research Center (DKFZ) Im Neuenheimer Feld 280 69120 Heidelberg Germany aubry.miller@dkfz.de.

RSC Advances
|November 2, 2022
PubMed

Related Concept Videos